Clinical Trials in Cleveland

Showing 2701-2720 of 16,969 trials

Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension

NCT06992440

Randomized, triple-masked, parallel arm clinical trial of empagliflozin versus placebo in pulmonary arterial hypertension (PAH) participants on stable approved PAH-targeted medical therapy.

Pulmonary Arterial Hypertension

Gustavo A Heresi, MD, MS78 participantsStarted Jun 2025

Baltimore, Maryland, United States • Cleveland, Ohio, United States • Nashville, Tennessee, United States

Active Not RecruitingPhase 2< 1 mile

Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer

NCT03092856

This randomized phase II trial studies how well axitinib with or without anti-OX40 antibody PF-04518600 work in treating patients with kidney cancer that has spread to other parts of the body. Biological therapies, such as anti-OX40 antibody PF-04518600, use substances made from living organisms that may may stimulate the immune system in different ways and stop tumor cells from growing. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving axitinib with or without anti-OX40 antibody PF-04518600 may work better in treating patients with kidney cancer.

Clear Cell Renal Cell CarcinomaMetastatic Renal Cell CancerRecurrent Renal Cell Carcinoma+1 more

University of Southern California62 participantsStarted Jul 2017

Los Angeles, California, United States • Los Angeles, California, United States • Newport Beach, California, United States +7 more locations

Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension

Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer

Find Trials by Condition in Cleveland

Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis

Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX

Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors

Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens

A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease

A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder

Post Approval Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough

A Phase 1/2 Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1)

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer

A Peer-Led Intervention to Improve Postpartum Retention in HIV Care

A Multicenter, Prospective Blood Collection Study in a Kidney Transplant Population

A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG